Regulatory Growing Pains Heat Up Cold Chain

Regulatory Growing Pains Heat Up Cold Chain
Biologics companies face a unique paradox. Inconsistent regulations surrounding their in-transit production one hand, and a Byzantine shipping process on the other, result in clinical delays, and ultimately potential financial losses. Streamlining the cold chain, and aligning the priorities of shippers, handlers, and legislators, are paramount, both to improve the current state of the industry and to future global healthcare.

If you prefer to receive a copy via email contact us at enquiryIQPC@iqpc.com


Please note: That all fields marked with an asterisk (*) are required.